|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||344.459 g·mol−1|
|3D model (JSmol)|
ADB-PINACA is a cannabinoid designer drug that is an ingredient in some synthetic cannabis products. It is a potent agonist of the CB1 receptor and CB2 receptor with EC50 values of 0.52 nM and 0.88 nM respectively. Like MDMB-FUBINACA, this compound contains an amino acid residue of tert-leucine.
ADB-PINACA has been linked to multiple hospitalizations and deaths due to its use.
Nineteen ADB-PINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Major metabolic reactions included pentyl hydroxylation, hydroxylation followed by oxidation (ketone formation), and glucuronidation.
ADB-PINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.
In the United States, it is a Schedule I controlled substance.
As of October 2015 ADB-PINACA is a controlled substance in China.